Skip to main content

pegfilgrastim (Neulasta®)

 

Following a full submission

AWMSG advice

Status: Recommended with restrictions

Pegfilgrastim (Neulasta®) is recommended as an option for restricted use within NHS Wales for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Its use should be restricted to patients where the risk of febrile neutropenia is high and where the risk of neutropenia from chemotherapy is likely to be prolonged (more than six days) or for patients with special circumstances e.g. geographical access, needle phobia. Pegfilgrastim (Neulasta®) is not suitable for shared care within NHS Wales.

 Final Recommendation: pegfilgrastim (Neulasta) 242 (PDF, 248Kb)

Medicine details

Medicine name pegfilgrastim (Neulasta®)
Formulation solution for injection
Reference number 242
Indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

Company Amgen Ltd
BNF chapter Nutrition & blood
Submission type Full
Status Recommended with restrictions
Advice number 1508
NMG meeting date 16/07/2008
AWMSG meeting date 13/08/2008
Ratification by Welsh Government 29/09/2008
Date of issue 06/10/2008
Follow AWTTC: